Takeda partners Evox on exosome tech

Evox Therapeutics logo

22nd March 2020

Pharmaceutical giant Takeda has partnered Evox Therapeutics, a spinout from the University, on the latter’s exosome technology.

Evox’s exosome tech opens up an exciting new avenue of drug delivery and an entirely novel class of biotherapeutics. It is hoped that the technology can be used to treat a range of rare conditions.

The deal with Takeda could be worth up to $882m in total if certain milestones are met, and includes an upfront payment of $44m.

Press release sign up

Ready to get in touch?

Contact Us
© Oxford University Innovation